Nutritherapy seeks to prevent or correct disease by the use of nutritional supplements including vitamins, trace elements, or macronutrients. This chapter of the “Les Entretiens du Carla” reviews the potential of nutritherapy for the prevention or improvement of sarcopenia, which is the progressive reduction in muscle mass and muscle strength prevalent in late-life. It is critical that we review nutrients and their potential to maintain muscle mass and strength which ultimately will help minimize falls and fractures among the older population. Evidence from randomized-controlled trials will be reviewed for muscle mass as well as important sarcopenia-related endpoints including lower extremity strength and function, as well as falls and fall-related fractures. This chapter will focus on vitamin D as a compelling strategy with evidence for strength gain, fall and fracture prevention from double-blind randomized controlled trials. The other strategy discussed is increased protein intake although longer-term trials and evidence for clinically important endpoints are limited. Today, there is no consistent data on other micronutrients or macronutrients with an established potential to combat sarcopenia.

The sarcopenia challenge in fracture prevention at older age

Critical for the understanding and prevention of fractures at later age is their close relationship with sarcopenia (muscle weakness) (1), and falling (2, 3). Over 90% of fractures occur after a fall and fall rates increase with age (4) and poor muscle strength or function (Figure 1) (4). Notably, anti-resorptive treatment alone may not reduce fractures among individuals 80 years and older in the presence of non-skeletal risk factors for fractures, such as muscle weakness and falling, despite an improvement in bone metabolism (5). Moreover, low muscle strength is an independent predictor of functional decline (6) and poor bone quality (7) among older adults.

Today, vitamin D is the only known strategy and only nutritherapy that has the comprehensive potential of strength improvement, as well as evidence for fall and fracture prevention among older individuals as documented in randomized controlled trials (RCTs).

**Vitamin D: prevalence of deficiency and risk factors**

Prevalence of severe vitamin D deficiency (25-hydroxyvitamin D levels < 30 nmol/l or < 12 ng/ml) is still high in older individuals, while desirable vitamin D levels of at least 75 nmol/l (30 ng/ml) for optimal muscle and bone health is reached by less than 30% of the US older population and less...
than 20% by the European older population (8, 9).

A 1999 landmark publication in the Journal of the American Medical Association (JAMA) by LeBoff and colleagues documented a 50% prevalence of severe vitamin D deficiency among postmenopausal women admitted with acute hip fracture (serum 25(OH)D levels < 30 nmol/l)[10]. The authors suggested in 1999 that heightened awareness is necessary to ensure adequate vitamin D nutrition, especially as vitamin D deficiency is preventable. The high prevalence of severe vitamin D deficiency among hip fracture patients has been confirmed in the early and late nineties by several studies from Europe (11-19). According to Swiss data published in 2008, the prevalence of severe 25(OH)D deficiency is still significant and basically unchanged compared to earlier data with a more than 50% prevalence of severe deficiency among hip fracture patients admitted from home and a 75% prevalence of severe deficiency among those admitted from institutions (20). Notably, less than 10% of 222 hip fracture patients investigated had any dose of vitamin D supplementation upon admission to acute care (20).

Most vulnerable to low vitamin D levels are older individuals (21, 22), individuals living in northern latitudes with prolonged winters (23, 24), obese individuals (25), and African Americans of all ages (26-28). Older individuals are at high risk of low vitamin D status because of the decreased production of vitamin D in the skin with age after sun exposure, which is 4-fold lower compared to younger adults (29). Furthermore, among older adults and within Europe lowest 25-hydroxyvitamin D levels are measured in Southern Europe (30), which may be explained by sun avoidance and sun protection at older age. Finally, nutritional sources of vitamin D are rare and are mostly limited to fatty fish, such as salmon, which is not regularly consumed in 2 servings and each day (31). Additionally, food fortification with vitamin D is not practiced in Europe as it is in the US, although the small benefit of about 200 IU vitamin D through consumption of fortified milk or orange juice in the US is small and did not prevent a further decline in 25- hydroxyvitamin D status among US adults as documented in the newest NHANES study (oral presentation of Prof. Bess Dawson-Hughes; IANA conference Boston 2007).

**Vitamin D: its role in muscle health**

In humans, four lines of evidence support a role of vitamin D in muscle health and the prevention of sarcopenia. First, proximal muscle weakness is a prominent feature of the clinical syndrome of vitamin D deficiency. Second, VDR is expressed in human muscle tissue, and VDR activation may promote de novo protein synthesis in muscle (32). Third, several observational studies suggest a positive association between 25-hydroxyvitamin D and muscle strength or lower extremity function in older persons (33, 34). Finally, in several double-blind randomized controlled trials, vitamin D supplementation increased muscle strength and balance (35, 36), and reduced the risk of falling in community-dwelling individuals (36-38), as well as in institutionalized individuals (35, 39). Notably, a study by Glurup and colleagues suggest that vitamin D deficiency may cause muscular impairment even before adverse effects on bone occur (40).

Mice without the VDR develop a skeletal muscle phenotype with smaller and variable muscle fibers and persistence of immature muscle gene expression during adult life (41). These abnormalities persist after correction of systemic calcium metabolism by a rescue diet (42).

**Vitamin D: desirable vitamin D status for better function and lower risk of sarcopenia**

A dose-response relationship between vitamin D status and muscle health was examined in NHANES III including 4100 ambulatory adults age 60 years and older. Muscle function measured as the 8-foot walk test and the repeated sit-to-stand test was poorest in subjects with the lowest 25-hydroxyvitamin D (below 20 nmol/l) levels. Similar results were found in a Dutch cohort of older individuals (33). Notably, while from the smaller Dutch cohort a threshold of 50 nmol/l has been suggested for optimal function (33), a threshold beyond which function would not further improve was not identified in NHANES III even beyond the upper end of the reference range (> 100 nmol/l)[34] with a similar benefit by gender, level of physical activity, and calcium intake. With respect to sarcopenia, appendicular skeletal muscle mass was measured in the Dutch cohort among 331 older adults using dual-energy x-ray absorptiometry. After a 3-yr follow-up, and after adjustment for physical activity level, season of data collection, serum creatinine concentration, chronic disease, smoking, and body mass index, persons with low (<25 nmol/l) baseline 25-hydroxyvitamin D levels were 2.14 (0.73-6.33, based on muscle mass) times more likely to experience sarcopenia, compared with those with higher (>50 nmol/l) levels. The associations were similar in men and women.

**Vitamin D: weakness / sarcopenia**

Muscle weakness is a prominent feature of the clinical syndrome of vitamin D deficiency. Clinical findings in vitamin D deficiency myopathy include proximal muscle weakness, diffuse muscle pain, and gait impairments such as waddling way of walking (43). The VDR is expressed in human muscle tissue (44), and vitamin D bound to its nuclear receptor in muscle tissue may lead to de novo protein synthesis (32, 45). One uncontrolled biopsy trial in postmenopausal women with osteoporosis documented a relative increase in the diameter and number of type II muscle fibers after a 3 month treatment with 1-alpha-calcidiol (32). These findings were confirmed by three recent double-blind RCTs with 800 IU vitamin D3 resulting in a 4-11% gain in lower extremity strength or function (35, 36), and an up to 28% improvement in body sway (36, 38) in older adults age 65+ between 2 to 12 month of treatment.
Vitamin D: fall prevention

Summarizing 5 high-quality double-blind RCTs (n = 1237), a meta-analysis published in 2004 found that vitamin D reduced the risk of falling by 22% (pooled corrected OR = 0.78; 95% CI [0.64, 0.92]) compared to calcium or placebo (46). This risk reduction was independent of the type of vitamin D, duration of therapy, and gender. For the two trials with 259 subjects using 800 IU of cholecalciferol per day over 2 to 3 months (35, 38), the corrected pooled OR was 0.65 (95% CI [0.40, 1.00]) (46), while 400 IU was insufficient in reducing falls (47). The importance of dose of vitamin D in regard to anti-fall efficacy was confirmed by one multi-dose double-blind RCT among 124 nursing home residents receiving 200, 400, 600 or 800 IU vitamin D compared to placebo over a 5 month period (39). Participants in the 800 IU group had a 72% lower rate of falls than those taking placebo or a lower dose of vitamin D (rate ratio=0.28; 95% confidence interval=0.11-0.75) (39).

Long-term supplementation over 3 years with 700 IU D3 plus 500 mg calcium among community-dwelling older women reduced the odds of falling by 46% (OR = 0.54; 95% confidence interval, 0.30-0.97) (37). Similarly, long-term supplementation among institutionalized individuals with ergocalciferol for 2 years, initially 10,000 IU given once weekly and then 1,000 IU daily, reduced the incident rate ratio for falling by 26% (RR = 0.73, 95% CI, 0.57-0.95) (48). A 49% fall reduction among older individuals with a history of a fall was demonstrated in a most recent 12-month trial with 1000 IU ergocalciferol compared to placebo (OR = 0.61; 95% confidence interval [CI], 0.37-0.97) (49).

The most up-to-date meta-analysis with a focus on anti-fall efficacy from 8 high-quality double-blind RCTs of supplemental confirms a benefit of vitamin D supplementation on fall prevention at a dose of at least 700 IU vitamin D per day (1).

Vitamin D: anti-fracture efficacy

A 2009 meta-analysis of 12 double-blind RCTs for non-vertebral fractures (n=42,279) and 8 RCTs for hip fractures (n = 40,886) found that anti-fracture efficacy of vitamin D is dose-dependent and increases significantly with a higher achieved level of 25-hydroxyvitamin D in the treatment group starting at 75 nmol/l (2). No fracture reduction was observed for a received dose of 400 IU or less per day, while a higher received dose of 482 to 770 IU supplemental vitamin D per day reduced non-vertebral fractures by 20% (pooled RR = 0.80; 95% CI, 0.72 -0.89; n = 33,265 from 9 trials) and hip fractures by 18% (pooled RR = 0.82; 95% CI, 0.69 -0.97; n = 31,872 from 5 trials). Notably, subgroup analyses for the prevention of non-vertebral fractures with the higher received dose suggested a significant benefit in all subgroups of the older population, independent of dwelling, age and additional calcium supplementation (see Table 1).

### Table 1

<table>
<thead>
<tr>
<th>Subgroups by received dose of vitamin D</th>
<th>Fracture reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pooled analysis from 3 trials with low-dose vitamin D (340-380 IU / day)</td>
<td>+2%</td>
</tr>
<tr>
<td>Pooled analysis from 9 trials with higher dose vitamin D (482-770 IU / day): Pooled subgroup analysis from trials with higher dose vitamin D (482-770 IE / Tag):</td>
<td>-20%</td>
</tr>
<tr>
<td>- Vitamin D2</td>
<td>-10%</td>
</tr>
<tr>
<td>- Vitamin D3</td>
<td>-23%</td>
</tr>
<tr>
<td>- age 65-74</td>
<td>-33%</td>
</tr>
<tr>
<td>- age 75+</td>
<td>-17%</td>
</tr>
<tr>
<td>- institutionalized 65+</td>
<td>-15%</td>
</tr>
<tr>
<td>- community-dwelling 65+</td>
<td>-29%</td>
</tr>
<tr>
<td>- Vitamin D plus Calcium</td>
<td>-21%</td>
</tr>
<tr>
<td>- Vitamin D main effects</td>
<td>-21%</td>
</tr>
</tbody>
</table>


Vitamin D: dosing and safety

Vitamin D intakes that may be required to achieve the optimal levels of 25(OH)D in most individuals are not established. Studies suggest that 700 to 1000 IU of vitamin D per day may bring 50% of younger and older adults up to 75-100 nmol/l (54-56). Thus, to bring most adults to the desirable range of 75-100 nmol/l, vitamin D doses higher than 700-1000 IU would be needed. The current intake recommendation for older persons (600 IU per day) may bring most subjects to 50-60 nmol/l, but not to 75-100 nmol/l (27). A recent risk assessment on vitamin D based on relevant, well-designed human clinical trials of vitamin D documented the absence of toxicity in trials conducted in healthy adults that used vitamin D dose 10,000 IU vitamin D3 (57). The authors thus suggested an upward adjustment of the safe upper limit from currently 2000 IU to 10,000 IU per day. Higher dose trials in older populations using 2000 IU vitamin D per day are being conducted for strength and fall endpoints. In clinical practice, older adults or obese individuals often start treatment from severe deficiency which requires higher doses of vitamin D to achieve the shift into the adequate range of 25-hydroxyvitamin D status (58, 59). In these situations a starting oral bolus of 30,000 to 100’000 IU once (60) followed by a daily or intermittent regimen with vitamin D is useful. Monitoring of 25-hydroxyvitamin D levels may be ideal to ensure sufficient vitamin D supplementation with a target range of 25-hydroxyvitamin D between 75 to 100 nmol/l (9). With a half-life of about 1.5 month, a control 25-hydroxyvitamin D serum level after 6 weeks of treatment is valuable.
Vitamin D: Combination with Calcium

Emerging data suggests that vitamin D may reduce falls and fractures independent of additional calcium supplementation provided the vitamin D intake is adequate (at least 800 IU per day) and dietary calcium intake is between 700 to 800 mg per day (2, 50, 51, 53). This is of clinical importance as calcium supplementation is not well tolerated in older adults resulting in low adherence to treatment (61).

Furthermore, with a lower minimal target for total calcium intake of 700-800 mg per day (the recommended minimal intake in the UK is 700 mg/day as oppose to 1200 mg in the US), dietary requirements may be met by nutritional intakes alone. Milk products could serve as a source of not only calcium but also high-quality protein, which may be a compelling strategy in the combat of sarcopenia if combined with a vitamin D supplement (see protein section).

Vitamin D: summary and future research

In summary, although RCT data regarding the vitamin D effect on sarcopenia are missing, high-quality RCT data for strength, balance, function, falls and fractures endpoints are appealing and show a significant benefit of vitamin D at a dose of at least 700 IU vitamin D per day. Additional data discussed in this chapter linking vitamin D to sarcopenia prevention are several: the documented presence of the VDR in human muscle tissue and its decline with age (62), prospective cohort data that suggest a 2-fold increased risk of sarcopenia measured by DEXA in older individuals with severe vitamin D deficiency (63), uncontrolled trial data that suggest a relative increase in type II muscle fibres with vitamin D treatment (32), and a clear dose-response association between higher 25-hydroxyvitamin D levels and lower extremity function from 2 epidemiologic studies (33, 34).

The dose-response relationships between higher doses of vitamin D or higher achieved 25-hydroxyvitamin D levels on the one hand and better function, greater fall and fracture reduction on the other, suggest that higher doses of vitamin D beyond 700-800 IU per day should be explored in future research to optimize prevention of sarcopenia and its adverse events.

Protein: Its potential and complexities

Daily consumption of protein declines with age, while there is general agreement that a sufficient protein intake may enhance muscle protein anabolism. A decrease in protein intake is therefore viewed as a likely contributor to age-related sarcopenia. Importantly, several studies suggest that the recommended daily allowance for protein may not be adequate for older people to maintain skeletal muscle mass (64, 65). Conceptually, the estimation of the RDA has several limitations, one being that it was calculated based on nitrogen balance studies, which is not a clinically relevant endpoint. Another being that the data were collected among young men, which may not extrapolate to older people who likely need a higher protein intake to maintain their nitrogen balance (64). However, even with the current target RDA of 0.8 g/kg/d for all adults, between 15-38% of adult men and 27-41% of adult women have dietary protein intakes below the RDA (64).

Beyond the lack of long-term data, the complexity of a higher protein recommendation among older persons is several: one concern is that renal function declines with age and high protein intake, particularly high intake of nondairy animal protein, may accelerate renal function decline in those with mild renal insufficiency (66). Some data also suggest that aging impairs digestability and bioavailability of some protein sources (67). For milk protein, protein gain was greater with whey protein (rapidly digested protein), and lower with caseins (slowly digested protein) in older men as opposed to younger men where the pattern was inverse (67).

Furthermore, it has been shown that other non-protein energy sources, such as carbohydrates affect protein metabolism, which may be most pronounced in older persons (68). Finally, protein supplementation in older persons may result in a compensatory decrease of voluntary food intake (69). These complexities and lack of longer-term data for important clinical endpoints challenge future research in sarcopenia prevention with higher protein intake (70).

References


